DBV Technologies | DBVT - 债务利息支出



金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 696.7M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


债务利息支出 更改 日
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amarin USD 3K 5K 2024-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
DBV Technologies USD 461K 323.71K 2025-03
Esperion Therapeutics USD 22.64M 585K 2025-12
Galectin Therapeutics USD 1.27M 220K 2024-06
Halozyme Therapeutics USD 5.51M 597K 2026-03
Incyte USD 569K 13K 2026-03
Insmed USD 20.08M 517K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
United Therapeutics USD 3.1M 100K 2025-12